查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1809914

2025-2030 年全球脊髓灰質炎聯合疫苗市場預測（按疫苗類型、接種途徑、技術、開發階段和最終用戶分類）

Combined Polio Vaccine Market by Vaccine Type, Route Of Administration, Technology, Development Stage, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計脊髓灰質炎疫苗市場規模到 2024 年將達到 26.3 億美元，到 2025 年將達到 27.4 億美元，到 2030 年將達到 33.4 億美元，複合年成長率為 4.01%。

主要市場統計數據
基準年2024年 26.3億美元
預計2025年 27.4億美元
預測年份 2030 33.4億美元
複合年成長率（%） 4.01%

小兒麻痺仍是全球疾病根除工作中最持久的目標之一，而聯合疫苗製劑現已成為各種醫療環境中高效免疫策略的支柱。聯合脊髓灰質炎疫苗將脊髓灰質炎脊髓灰質炎病毒抗原整合到一劑疫苗中，簡化了複雜的供應鏈管理，減少了先前阻礙干預的低溫運輸株和物流限制。無論是在覆蓋率高的常規免疫規劃中，還是在快速應對疫情的宣傳活動中，這些聯合製劑都已證明能夠在加快覆蓋率的同時保持強大的安全性和有效性。因此，從國際衛生組織到國家衛生署的相關人員將聯合脊髓灰質炎疫苗視為邁向無脊髓灰質炎世界的最後一搏的關鍵工具。

此外，聯合疫苗研發的進展反映了尖端病毒學、先進佐劑科學和即時藥物安全檢測系統的整合。生物技術創新者與公共部門免疫計畫之間的近期合作，催生了新型呈現抗原技術，該技術可最佳化免疫系統的啟動，並減少副作用。這些進展與數位追蹤平台相輔相成，增強了批次級可追溯性和低溫運輸完整性，從而提高了疫苗從生產到接種的可行性。因此，脊髓灰質炎聯合疫苗如今在更廣泛的多疾病免疫平台中佔據戰略地位，有助於加強全球衛生安全目標。

本執行摘要提煉了影響脊髓灰質炎疫苗組合市場格局的關鍵趨勢、變化和外部壓力。它深入分析了近期關稅政策的累積影響，並揭示了按劑型、給藥途徑、技術、開發階段和最終用戶類型分類的細分動態，重點介紹了推動美洲、歐洲、中東和非洲以及亞太地區需求的區域差異。此外，它還提供了主要企業的策略分析、為產業決策者提供的可行建議，以及對這些研究結果所依據的嚴謹調查方法的概述。摘要最後提出了下一代免疫計畫的策略建議。

揭示疫苗研發和分發的變革性轉變，將重新定義全球脊髓灰質炎疫苗接種

在技​​術創新、法規不斷演變以及公私合作日益加強的推動下，脊髓灰質炎聯合疫苗領域近年來經歷了一系列變革。疫苗研發人員正在利用平台技術實現抗原模組化，大幅縮短下一代製劑的臨床推廣時間。同時，全球衛生組織改進了核准途徑，加快了緊急使用授權，以便在疫情爆發時快速部署聯合劑量。這些監管改進統一了各主要市場的核准標準，為大規模生產和分銷創造了更可預測的環境。

評估2025年美國關稅對脊髓灰質炎疫苗製造供應鏈和全球成本結構的累積影響

2025年美國新關稅的實施，為脊髓灰質炎疫苗供應鏈帶來了複雜的挑戰和策略考量。原料採購，尤其是生技藥品級佐劑和管瓶，將面臨更高的進口關稅，進而對生產成本造成上行壓力。因此，製造商正在重新評估籌資策略策略，重新協商供應商契約，並將生產轉移到提供優惠貿易條件的國家。這導致供應鏈更加多元化，一些公司在東南亞和東歐建立了二級採購點，以對沖關稅造成的成本波動。

重點細分分析，重點在於疫苗類型、給藥途徑、技術、開發階段和最終用戶的市場動態

分段分析揭示了不同疫苗類型的不同發展軌跡，由於抗原譜最佳化和低溫運輸要求簡化，二價疫苗迅速成為常規免疫的預設選擇。當流行病學調查中發現單一脊髓灰質炎病毒血清型時，單價疫苗透過以免疫學為重點的免疫接種，對於有針對性地控制疫情具有戰略重要性。同時，三價疫苗仍然是廣譜保護的基礎，尤其是在優先考慮同時針對多種脊髓灰質炎株進行免疫接種的項目中。

重點介紹美洲、歐洲、中東和非洲地區以及亞太地區的市場驅動力和挑戰

在美洲，完善的疫苗接種基礎設施和穩定的監管途徑造就了成熟的市場，其特點是高疫苗接種覆蓋率。該地區的公私合作夥伴關係注重持續品質改進，並整合了先進的低溫運輸監控系統和數位記錄平台，有助於確保都市區和偏遠地區的疫苗接種率。

分析推動全球聯合脊髓灰質炎疫苗領域發展的領先企業夥伴關係和創新

業內參與者採取了各種策略方針，以確保在脊髓灰質炎聯合疫苗領域的主導。跨國製藥公司透過瞄準和收購專業的生物技術開發公司，擴大了其產品組合。這種整合加速了獲取新型抗原平台和重組表現系統的途徑，這些平台和系統可作為下一代製劑的基礎。同時，新興生物科學公司已與成熟製造商建立了許可合作夥伴關係，以利用互補的規模化能力，推動創新候選疫苗進入後期臨床試驗和分銷階段。

為行業領導者提供可行的建議，以策略優先排序和投資脊髓灰質炎疫苗的開發和分發

為了最大限度地拓展脊髓灰質炎聯合疫苗的開發和商業化機會，產業領導者應優先投資於能夠增強抗原穩定性和免疫抗原性的先進佐劑和載體技術。透過將研發資源投入次單元和重組平台，企業可以提供差異化的安全性、耐熱性和簡化的低溫運輸要求。這種專注的努力將加快監管核准，並擴大先前因基礎設施限制而覆蓋範圍有限的地區的疫苗可及性。

嚴謹的調查方法和資料收集框架的詳細資訊，為綜合分析脊髓灰質炎疫苗市場動態奠定基礎

本研究採用嚴謹的調查方法，將深入的二手資料收集與有針對性的一手資料研究結合，確保了研究的穩健性和有效性。二級資訊來源包括同行評審期刊、監管備案文件、技術白皮書和臨床試驗註冊庫，從而能夠全面審查製劑技術、安全性概況和生產最佳實踐。此外，我們也透過評估疫苗市場相關領域和免疫接種項目，進一步闡述了這些見解。

摘要關鍵發現並強調相關人員在製定脊髓灰質炎聯合疫苗接種計劃方面的策略要務

脊髓灰質炎聯合疫苗領域正處於關鍵的十字路口，技術創新、供應鏈韌性和公平可及性是其共同面臨的挑戰。關鍵洞察包括：常規免疫計畫中二價製劑的興起、口服和注射給藥途徑的持續價值，以及正在重新定義耐熱標準的次單元技術的興起。此外，2025年的關稅趨勢正在推動供應鏈多元化和在地化生產，從而增強該產業的策略適應性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 開發新型佐劑技術以增強資源有限環境中的黏膜和體液免疫
  • 加強監管協調，加速新版統一分次去活化脊髓灰質炎疫苗接種計畫的核准
  • 臨床試驗數據表明，含有脊髓灰質炎成分的六價疫苗在低收入國家具有非劣效免疫抗原性
  • 透過與全球衛生組織和新興生物技術公司的策略夥伴關係實現在地化製造
  • 在聯合疫苗中引入分劑量皮內注射IPV，以解決全球供不應求

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8.脊髓灰質炎聯合疫苗市場（依疫苗類型）

  • 二價疫苗
  • 單價疫苗
  • 三價疫苗

9.脊髓灰質炎聯合疫苗市場（依接種途徑）

  • 注射
  • 口服

10.脊髓灰質炎聯合疫苗市場（依技術）

  • 去活化脊髓灰質炎病毒疫苗
  • 減毒活疫苗
  • 次單位疫苗

11.脊髓灰質炎聯合疫苗市場（依發展階段）

  • I期臨床試驗
  • II期臨床試驗
  • III期臨床試驗
  • 臨床前試驗

12.脊髓灰質炎聯合疫苗市場（依最終用戶）

  • 診所
  • 社區健康中心
  • 醫院
  • 公共衛生實驗室

13.美洲脊髓灰質炎聯合疫苗市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

14. 歐洲、中東和非洲聯合脊髓灰質炎疫苗市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區聯合脊髓灰質炎疫苗市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Astellas Pharma Inc.
    • Bharat Immunologicals and Biologicals Corporation Limited
    • AstraZeneca PLC
    • Biological E. Limited
    • BioNTech SE
    • CSL Limited
    • Daiichi Sankyo Company, Limited.
    • GlaxoSmithKline PLC
    • Haffkine Bio-Pharmaceutical Corporation Ltd
    • Incepta Pharmaceuticals Ltd.
    • Merck & Co., Inc.
    • Mitsubishi Tanabe Pharma Corporation
    • Panacea Biotec Ltd.
    • Pfizer Inc.
    • Sanofi SA
    • Serum Institute of India Pvt. Ltd.
    • Sinovac Biotech Ltd.
    • Takeda Pharmaceutical Company Limited
    • Zydus Lifesciences Limited

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-3E7318E8371A

The Combined Polio Vaccine Market was valued at USD 2.63 billion in 2024 and is projected to grow to USD 2.74 billion in 2025, with a CAGR of 4.01%, reaching USD 3.34 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.63 billion
Estimated Year [2025] USD 2.74 billion
Forecast Year [2030] USD 3.34 billion
CAGR (%) 4.01%

Poliomyelitis remains one of the most enduring targets in global disease eradication initiatives, with combined vaccine formulations now forming the backbone of efficient immunization strategies across diverse healthcare environments. By consolidating multiple poliovirus antigens within a single dose, combined polio vaccines have streamlined the complexities of supply chain management, reducing cold chain burdens and logistical constraints that once hindered outreach efforts. In both high-coverage routine immunization programs and rapid response campaigns to emergent outbreaks, these integrated formulations have demonstrated a capacity to accelerate coverage rates while maintaining robust safety and efficacy profiles. As a result, stakeholders from international health bodies to national ministries of health view combined polio vaccines as pivotal tools in the final push toward a polio-free world.

Moreover, the evolution of combined vaccine development reflects a convergence of cutting-edge virology, advanced adjuvant science, and real-time pharmacovigilance systems. Recent collaborations between biotech innovators and public sector immunization programs have produced novel antigen presentation technologies that optimize immune system priming with fewer side-effect trade-offs. These advancements have been complemented by digital tracking platforms that enhance batch-level traceability and cold chain integrity, ensuring higher rates of vaccine viability from production to point of administration. Consequently, combined polio vaccines now occupy a strategic position within broader multi-disease immunization platforms, reinforcing global health security objectives.

This executive summary distills the key trends, transformative shifts, and external pressures shaping the combined polio vaccine landscape. It delivers insights into the cumulative impact of recent tariff policies, unveils segmentation dynamics by formulation, administration route, technology, development stage, and end-user type, and highlights the regional nuances driving demand across the Americas, Europe, Middle East and Africa, and Asia-Pacific. In addition, it presents an analysis of leading company strategies, actionable recommendations for industry decision-makers, and an overview of the rigorous research methodology underpinning these findings. The summary concludes with strategic imperatives designed to inform the next generation of immunization initiatives.

Unveiling the Transformative Shifts in Vaccine Development and Distribution That Are Redefining the Polio Immunization Landscape Worldwide

The combined polio vaccine arena has undergone a series of transformative shifts over recent years, driven by technological innovation, evolving regulatory frameworks, and heightened collaboration across the public and private sectors. Vaccine developers have harnessed platform technologies that allow for modular antigen incorporation, significantly reducing time-to-clinic for next-generation formulations. Concurrently, global health agencies have refined licensure pathways to expedite emergency use authorizations, ensuring rapid deployment of combined doses during outbreak scenarios. These regulatory refinements have harmonized approval standards across key markets, fostering a more predictable environment for large-scale production and distribution.

In parallel, the advent of decentralized manufacturing models has disrupted traditional centralized production hubs. Strategic investments in regional fill-finish facilities now enable closer proximity to target populations, mitigating transportation risks and minimizing inventory aging. Digital thermosensitivity sensors and blockchain-enabled traceability systems have further increased supply chain resilience, enabling real-time visibility into vaccine integrity from factory floor to frontline clinics. As a result, immunization campaigns can pivot more nimbly in response to emergent epidemiological data, aligning inventory allocation with localized outbreak profiles and vaccination coverage gaps.

Furthermore, the integration of combined polio vaccines into broader multiplexed immunization schedules has catalyzed new public-private partnerships. Vaccine alliances are coordinating end-to-end distribution networks, co-funding community engagement initiatives, and deploying mobile immunization units equipped with cold chain autonomy. These collaborative models are breaking down historical silos between sector stakeholders, ensuring that combined polio vaccines are delivered with unprecedented speed and consistency to communities in need. Such shifts underscore the strategic imperative for manufacturers, policy makers, and global health organizations to align incentives around scale, access, and technological interoperability.

Assessing the Cumulative Impact of 2025 United States Tariffs on Combined Polio Vaccine Manufacturing Supply Chains and Cost Structures Globally

The implementation of new tariff measures by the United States in 2025 has introduced a complex set of challenges and strategic considerations for combined polio vaccine supply chains. Raw material sourcing, particularly of biologics-grade adjuvants and vials, has become subject to elevated import duties, exerting upward pressure on production expenditures. Consequently, manufacturers have been compelled to reevaluate procurement strategies, renegotiating supplier agreements or shifting production to jurisdictions offering preferential trade terms. This has prompted a wave of supply chain diversification, with several firms establishing secondary sourcing hubs in Southeast Asia and Eastern Europe to hedge against tariff-induced cost fluctuations.

At the same time, end-to-end manufacturing footprints are adapting to maintain both compliance and competitiveness. Vaccine producers have accelerated investments in onshore fill-finish capacity to partially neutralize tariff impact, deploying modular facilities that require lower capital expenditure and can scale in alignment with immunization campaign demands. While these localized operations offer a buffer against import duties, they also necessitate new regulatory submissions and quality assurance protocols, introducing additional layers of process complexity. Nevertheless, the strategic pivot toward more distributed manufacturing has enhanced supply chain adaptability and reduced lead times for critical orders.

Moreover, payer negotiations in both public and private healthcare channels are adjusting to accommodate the revised cost structures. Governments and procurement agencies are exploring volume-based agreements and risk-sharing frameworks to stabilize vaccine budgets. In parallel, global health financing bodies are recalibrating grant mechanisms to account for the residual tariff burden, ensuring immunization coverage targets remain within reach. Through these adaptive strategies, the sector is charting a path that balances fiscal sustainability with the imperative of maintaining uninterrupted access to life-saving combined polio vaccines.

Revealing Key Segmentation Insights That Illuminate Market Dynamics Across Vaccine Types Administration Routes Technologies Development Stages and End Users

Segmentation analysis reveals distinct trajectories across vaccine type categories, with bivalent formulations rapidly becoming the default choice for routine immunization due to their optimized antigenic profile and streamlined cold chain requirements. Monovalent variants retain strategic importance for targeted outbreak containment, offering heightened immunological focus when epidemiological surveillance identifies a single poliovirus serotype in circulation. Meanwhile, trivalent options continue to play a foundational role in broad-spectrum protection, particularly within programs prioritizing simultaneous immunity against multiple poliovirus strains.

Considering the route of administration, injectable combined polio vaccines remain predominant within hospital-based programs and clinical settings, where trained personnel administer doses under controlled conditions. Oral formulations, on the other hand, sustain their value in community outreach efforts, especially within remote or resource-constrained regions where ease of administration and minimal equipment requirements drive higher coverage metrics. Consequently, manufacturers are fine-tuning packaging formats and administration devices to meet the unique demands of each distribution channel.

From a technological standpoint, inactivated poliovirus vaccines maintain a leadership position owing to their established safety record and regulatory precedence. Live attenuated vaccines continue to serve crucial roles in outbreak response due to their robust mucosal immunity induction, while subunit vaccine candidates are emerging as next-generation solutions that promise enhanced thermostability and reduced reactogenicity. As these technological platforms advance through Phase I, Phase II, Phase III, and pre-clinical stages, clinical trial pipelines are diversifying, reflecting an industry impetus toward differentiated efficacy and safety profiles.

Finally, end-user segmentation illustrates varied adoption patterns: clinics and hospitals prioritize high-throughput, prefilled presentations for seamless integration into immunization schedules, whereas community health centers leverage lower-cost, bulk packaging to maximize resource allocation. Public health laboratories, tasked with batch release testing and cold chain monitoring, are instrumental in validating new product entries and ensuring compliance with stringent quality standards. Together, these segmentation insights illuminate the complex interplay of formulation, delivery method, technology, development progress, and end-user needs shaping the combined polio vaccine market.

Highlighting Critical Regional Insights That Uncover Growth Drivers and Challenges in the Americas Europe Middle East and Africa and Asia Pacific Markets

Regional dynamics underscore the divergent trajectories of combined polio vaccine adoption, beginning with the Americas, where well-established immunization infrastructures and stable regulatory pathways have fostered a mature market characterized by high coverage rates. In this region, public-private alliances emphasize continuous quality improvement, integrating advanced cold chain monitoring systems and digital record-keeping platforms to sustain robust vaccine uptake among both urban and remote populations.

Turning to Europe, the Middle East and Africa, collaborative networks have coalesced around shared public health objectives, leveraging pooled procurement mechanisms to secure favorable pricing and guarantee consistent supply. Regulatory harmonization initiatives among cooperating authorities have reduced approval lead times, while joint technical assistance programs support cold chain enhancements in areas with challenging logistics. As a result, combined polio vaccines are increasingly utilized within integrated immunization campaigns that address multiple vaccine-preventable diseases simultaneously.

In the Asia-Pacific region, the market is defined by rapid expansion of domestic manufacturing capacity and government-led immunization drives targeting hard-to-reach communities. Technology transfer agreements and local fill-finish partnerships have bolstered regional self-sufficiency, while tiered pricing frameworks ensure affordability across diverse income levels. Concurrent public awareness initiatives are enhancing caregiver education and demand generation, driving significant increases in both preventative routine coverage and reactive outbreak interventions. Collectively, these region-specific developments shape a multifaceted global landscape, requiring manufacturers and policy-makers to calibrate strategies that align with distinct regulatory, economic, and infrastructure considerations.

Analyzing Leading Corporate Strategies Partnerships and Innovations Driving Advancement in the Combined Polio Vaccine Sector Globally

Industry participants have adopted a range of strategic approaches to secure leadership in the combined polio vaccine domain, with multinational pharmaceutical firms expanding their portfolios through targeted acquisitions of specialized biotech developers. These integrations have accelerated access to novel antigen platforms and recombinant expression systems that underpin next-generation formulations. Concurrently, emerging bioscience companies are entering licensing partnerships with established manufacturers, leveraging complementary scale-up capabilities to bring innovative vaccine candidates through late-stage clinical trials and into distribution.

Strategic alliances with global health institutions have also emerged as key enablers of market penetration, as companies co-invest in infrastructure projects that strengthen cold chain resilience and enhance last-mile delivery. In parallel, technology innovators are collaborating on digital end-to-end traceability solutions that ensure product authenticity and real-time temperature monitoring, thereby mitigating spoilage risks and bolstering donor confidence.

Furthermore, a subset of manufacturers is differentiating through the development of combination therapies that integrate polio antigens with other childhood immunogens, streamlining immunization schedules and reducing the number of injections required over a child's first year. By pursuing regulatory designations that prioritize these multi-antigen presentations, companies aim to secure accelerated reviews and broaden their market reach. Across these varied strategic initiatives, a common thread emerges: the imperative to balance innovation speed with operational excellence, ensuring that combined polio vaccines remain accessible, reliable, and aligned with evolving public health priorities.

Providing Actionable Recommendations to Industry Leaders for Strategic Prioritization and Investment in Combined Polio Vaccine Development and Distribution

To capitalize on opportunities within the combined polio vaccine space, industry leaders should prioritize investment in advanced adjuvant and carrier technologies that enhance antigen stability and immunogenicity. By channeling research and development resources into subunit and recombinant platforms, companies can achieve differentiated safety profiles and thermal tolerances that simplify cold chain requirements. This focus will accelerate regulatory approvals and expand access in regions where infrastructure limitations have historically constrained coverage.

In addition, organizations must expand regional manufacturing footprints through modular, low-capex fill-finish facilities. Establishing localized production hubs not only mitigates tariff and logistics risks but also fosters stronger relationships with national health authorities. Accompanying these investments with targeted workforce training programs will ensure operational readiness and quality assurance compliance, positioning manufacturers to respond swiftly to outbreak demands.

Moreover, forging public-private partnerships that align procurement incentives with performance metrics can stabilize funding streams and reduce financial uncertainties. By negotiating volume-based contracts and outcome-linked payment models, companies and governments can distribute risk equitably while sustaining vaccine affordability. Simultaneously, embedding digital supply chain tracking systems will enhance transparency and facilitate dynamic allocation of inventory in response to real-time epidemiological data.

Finally, industry stakeholders should engage proactively in global regulatory harmonization forums to streamline clinical trial requirements and licensing processes. Shared technical guidelines and mutual recognition agreements will shorten time-to-market for novel combined polio formulations. Through these integrated strategies-spanning technological innovation, decentralized manufacturing, collaborative financing, and regulatory alignment-leaders can drive lasting improvements in polio immunization access and impact.

Detailing Rigorous Research Methodology and Data Collection Framework Underpinning the Comprehensive Analysis of Combined Polio Vaccines Market Dynamics

This research rested on a rigorous methodology that combined exhaustive secondary data collection with targeted primary consultations to ensure robustness and validity. Secondary sources included peer-reviewed journals, regulatory filings, technical white papers, and clinical trial registries, enabling a comprehensive review of formulation technologies, safety profiles, and manufacturing best practices. These insights were further contextualized through adjacencies in vaccine markets and immunization program evaluations.

Primary inputs were gathered via structured interviews with seasoned virologists, immunization program managers, supply chain experts, and regulatory affairs specialists. This qualitative engagement illuminated on-the-ground operational challenges and emerging opportunities, providing a nuanced understanding of both macro-level policies and micro-level execution realities. In addition, validation workshops with independent stakeholders served to cross-verify contentious data points and refine interpretation of tariff impacts and segmentation dynamics.

Analytical frameworks such as SWOT assessments, PESTLE analysis, and scenario planning underpinned the synthesis of findings, enabling a multi-dimensional exploration of competitive forces, geopolitical influences, and technological disruptions. Data triangulation techniques were applied at every stage, with iterative quality assurance processes ensuring that conflicting or anomalous inputs were reconciled. Ultimately, this blended methodology delivered a holistic perspective on combined polio vaccine market dynamics, equipping decision-makers with actionable intelligence grounded in empirical evidence and expert consensus.

Summarizing Core Findings and Emphasizing the Strategic Imperatives for Stakeholders in the Evolution of Combined Polio Vaccination Initiatives

The combined polio vaccine domain stands at a pivotal juncture, defined by concurrent imperatives for technological innovation, supply chain resilience, and equitable access. Core findings highlight the ascendancy of bivalent formulations in routine immunization programs, the sustained value of oral and injectable administration channels, and the emergence of subunit technologies poised to redefine thermostability standards. Moreover, the 2025 tariff landscape has catalyzed supply chain diversification and localized manufacturing investments, reinforcing the sector's strategic adaptability.

Regional nuances further underscore the importance of tailored approaches: the Americas' mature infrastructure and digital integration contrast with collaborative procurement models in Europe, the Middle East and Africa, and the rapid capacity-building initiatives underway in Asia-Pacific. Leading companies are responding with a spectrum of strategies, from cross-sector acquisitions to novel public-private partnership frameworks, all aimed at aligning innovation pipelines with global immunization objectives.

Strategic imperatives emerge from this analysis: fostering harmonized regulatory pathways, investing in modular production solutions, and embedding digital traceability within distribution networks. By operationalizing these recommendations, stakeholders can navigate policy volatility, enhance programmatic efficiency, and ultimately contribute to the enduring goal of global polio eradication. The convergence of technical advances and collaborative frameworks presents a unique window of opportunity to translate collective expertise into sustained public health impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Development of novel adjuvant technologies to boost mucosal and humoral immunity in resource-limited settings
  • 5.2. Regulatory harmonization efforts to accelerate approval of newly combined fractional inactivated polio vaccine schedules
  • 5.3. Clinical trial data demonstrating noninferior immunogenicity of hexavalent vaccines including polio components in low-income countries
  • 5.4. Strategic partnerships between global health organizations and emerging biotech firms to localize combined polio vaccine manufacturing
  • 5.5. Implementation of fractional dose intradermal IPV in combination vaccines to address global supply shortages

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Combined Polio Vaccine Market, by Vaccine Type

  • 8.1. Introduction
  • 8.2. Bivalent Vaccine
  • 8.3. Monovalent Vaccine
  • 8.4. Trivalent Vaccine

9. Combined Polio Vaccine Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Injectable Administration
  • 9.3. Oral Administration

10. Combined Polio Vaccine Market, by Technology

  • 10.1. Introduction
  • 10.2. Inactivated Poliovirus Vaccines
  • 10.3. Live Attenuated Vaccines
  • 10.4. Subunit Vaccines

11. Combined Polio Vaccine Market, by Development Stage

  • 11.1. Introduction
  • 11.2. Phase I Clinical Trials
  • 11.3. Phase II Clinical Trials
  • 11.4. Phase III Clinical Trials
  • 11.5. Pre-Clinical Trials

12. Combined Polio Vaccine Market, by End User

  • 12.1. Introduction
  • 12.2. Clinics
  • 12.3. Community Health Centers
  • 12.4. Hospitals
  • 12.5. Public Health Laboratories

13. Americas Combined Polio Vaccine Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Combined Polio Vaccine Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Combined Polio Vaccine Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Astellas Pharma Inc.
    • 16.3.2. Bharat Immunologicals and Biologicals Corporation Limited
    • 16.3.3. AstraZeneca PLC
    • 16.3.4. Biological E. Limited
    • 16.3.5. BioNTech SE
    • 16.3.6. CSL Limited
    • 16.3.7. Daiichi Sankyo Company, Limited.
    • 16.3.8. GlaxoSmithKline PLC
    • 16.3.9. Haffkine Bio-Pharmaceutical Corporation Ltd
    • 16.3.10. Incepta Pharmaceuticals Ltd.
    • 16.3.11. Merck & Co., Inc.
    • 16.3.12. Mitsubishi Tanabe Pharma Corporation
    • 16.3.13. Panacea Biotec Ltd.
    • 16.3.14. Pfizer Inc.
    • 16.3.15. Sanofi S.A.
    • 16.3.16. Serum Institute of India Pvt. Ltd.
    • 16.3.17. Sinovac Biotech Ltd.
    • 16.3.18. Takeda Pharmaceutical Company Limited
    • 16.3.19. Zydus Lifesciences Limited

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. COMBINED POLIO VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. COMBINED POLIO VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. COMBINED POLIO VACCINE MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. COMBINED POLIO VACCINE MARKET: RESEARCHAI
  • FIGURE 26. COMBINED POLIO VACCINE MARKET: RESEARCHSTATISTICS
  • FIGURE 27. COMBINED POLIO VACCINE MARKET: RESEARCHCONTACTS
  • FIGURE 28. COMBINED POLIO VACCINE MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. COMBINED POLIO VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY BIVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY BIVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY MONOVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TRIVALENT VACCINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TRIVALENT VACCINE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INJECTABLE ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INACTIVATED POLIOVIRUS VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY INACTIVATED POLIOVIRUS VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE I CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE II CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PRE-CLINICAL TRIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PRE-CLINICAL TRIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMBINED POLIO VACCINE MARKET SIZE, BY PUBLIC HEALTH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 54. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 55. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 56. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 57. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 58. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 59. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 60. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 63. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 66. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 67. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 68. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 69. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 70. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 71. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 73. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 74. UNITED STATES COMBINED POLIO VACCINE MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 75. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 78. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 79. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 80. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 81. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 82. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 83. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 84. CANADA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 85. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 88. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 89. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 90. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 91. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 92. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 93. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 94. MEXICO COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 95. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 98. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 99. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 102. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 103. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 104. BRAZIL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 105. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 108. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 109. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 110. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 111. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 112. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 113. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 114. ARGENTINA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED KINGDOM COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 137. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 140. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 141. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 143. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 144. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 145. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. GERMANY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 147. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 150. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 151. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 154. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 155. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. FRANCE COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 157. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 161. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 162. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 163. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 164. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 165. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 166. RUSSIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 167. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 171. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 172. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 173. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 174. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 175. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. ITALY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 177. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 180. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 181. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 184. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 185. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. SPAIN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 204. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. SAUDI ARABIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 213. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 214. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 215. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. SOUTH AFRICA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 217. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 220. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 221. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 224. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 225. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. DENMARK COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 232. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 234. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 236. NETHERLANDS COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 237. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 241. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 242. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 243. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 244. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 245. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. QATAR COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 247. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 251. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 252. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 253. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 254. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 255. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 256. FINLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 257. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 260. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 261. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 264. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 265. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. SWEDEN COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 267. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 271. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 272. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 273. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 274. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 275. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. NIGERIA COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 277. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 280. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 281. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 284. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 285. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EGYPT COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 287. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 291. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 293. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 294. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 295. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 296. TURKEY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 297. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 301. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 302. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 303. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 304. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 305. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. ISRAEL COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 307. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 311. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 313. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 314. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 315. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NORWAY COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 317. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 320. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
  • TABLE 321. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 322. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 323. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2024 (USD MILLION)
  • TABLE 324. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY DEVELOPMENT STAGE, 2025-2030 (USD MILLION)
  • TABLE 325. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 326. POLAND COMBINED POLIO VACCINE MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 327. SWITZERLAND COMBINED POLIO VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILL